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introduction & objectives: The lymphatic drainage of RCC is unpredictable and 
the role of lymph node dissection (LND) in RCC remains controversial despite a 
randomized study with a median follow up of 12.6 years. In addition, the introduction 
of targeted agents has revived interest in adjuvant treatment concepts. Accurate 
LN staging is warranted to determine the risk of recurrence or progression. Here 
we apply single-photon emission computed tomography (SPECT) in combination 
with computed tomography (CT) for preoperative identification of sentinel lymph 
nodes (SNs) and to investigate distribution and site of SN as well as surgical safety 
of intraoperative sampling.
Materials & Methods: An interim analysis of 21 patients from an ongoing 
prospective trial to investigate site and distribution of SN in RCC (NL26406.031.08). 
Patients underwent injection of 99mTc-nanocolloid into the renal tumour for 
preoperative identification of SN with SPECT/CTand subsequent removal of the 
tumour and intraoperative sampling using a gamma probe and portable camera. 
Lymphadenectomy was completed locoregionally.
results: SPECT/CT detected SN in 15/21 patients (71%), including 4 patients with 
non-visualisation on planar lymphoscintigraphy. Twenty-seven SN were seen; 17 
para-aortic(including interaorto-caval), 4 retrocaval, 2 hilar, 1 celiac trunc,1 internal 
mammary and 2 mediastinal and pleural. These latter 4 nodes were not harvested 
according to protocol. All other SN, except for 2 weakly radioactive interaorto-caval 
nodes, were identified and excised with a mean additional time of 20 minutes. 
None of the removed SN and locoregional nodes was tumor-bearing.
Conclusions: SN from RCC are mainly localized in the para-aortic region, but 
aberrant supradiaphragmal nodes receive direct drainage. Intraoperative SN 
identification and sampling in RCC with preoperative detection on SPECT/CT is 
surgically safe and feasible. Non visualisation of SN appears in almost a third 
of the patients. Further studies are required to demonstrate if accurate mapping 
of lymphatic drainage and extent of lymphatic spread may have diagnostic and 
therapeutic implications.
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introduction & objectives: To evaluate the prognostic role of histologic in a large 
multi-institutional series of patients undergoing radical or partial nephrectomy for 
renal cell carcinoma (RCC).
Materials & Methods: We collected retrospectively the data of 5378 patients who 
were surgically treated for RCC in 16 academic centers involved in the Surveillance 
And Treatment Update Renal Neoplasms (SATURN) project.
results: 4371 (81%) patients had clear cell RCC (ccRCC), 579 (11%) papillary 
RCC (pRCC), 291 (6%) chromophobe RCC (chRCC), 47 (1%) collecting duct RCC 
(cdRCC) , and 90 (2%) unclassified RCC (uRCC). At a median follow-up of 42 
months (IQR 24–75), 1055 patients (20%) had developed disease recurrence and 
786 (15%) were dead of RCC. 5-year cancer-specific survival (CSS) estimates 
were 78.1% in ccRCC, 85.6% in pRCC, 89.3% in chRCC, 55.6% in uRCC, and 
31.9% in cdRCC, respectively (pooled p value <0.0001). All the survival differences 
among the different subtypes were statistically significant (pairwise p values 
<0.02). On multivariable Cox regression analyses, histological subtype was an 
independent predictor of CSS (p <0.0001), once adjusted for the effect of all the 
other covariates. Specifically, both pRCC (H.R. 0.7; p=0.022), and chRCC (H.R. 
0.6; p=0.047) had higher CSS compared with ccRCC. Conversely, both cdRCC 
(H.R. 2.4; p=0.001) and uRCC (H.R. 1.7; p=0.007) had significantly worse outcome 
in comparisons with clear cell RCC.
Conclusions: Histological subtypes was an independent predictors of CSS. For 
the first time, time significant survival differences were demonstrated among all the 
major subtypes of RCC.
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introduction & objectives: DNA methylation is an essential epigenetic modification 
in carcinogenesis. In this study, methylation patterns in promotor-/exon-1-areas of 
selected genes were analyzed and quantified with the pyrosequencing technique 
to evaluate their applicability as potential diagnostic markers in prostate cancer.
Materials & Methods: We analyzed 71 prostate cancer samples (Gleason grade 
6-9) from prostatectomy specimens and compared them to normal prostatic tissue 
from the same patients. Additionally, cell lines LNCaP, PC-3 and DU-145 were used 
as system controls. After DNA isolation from paraffin sections applying QiaAMP 
FFPE micro kits and bisulfite conversion using EZ Amp Gold kits we performed 
pyrosequencing to evaluate CpG-island hypermethylation in 10 selected gene 
loci (APC, DAPK, Endoglin, GADD45a, GSTP1, p14, RASSF1A, RUNX3, 14-3-3 
Sigma and TNFRSF10C).
results: Successful DNA isolation, bisulfite conversion and pyrosequencing could 
be performed in all samples. On the basis of quantitative distinctions in promotor-/
exon-1-CpG-island methylation the following genes allowed significant determination 
of benigne and malignant tissue: GSTP1 (p<0.01), APC (p<0.01), RASSF1a 
(p<0.01), TNFRSF10C (p<0.01). Gene loci APC, RASSF1a and Endoglin showed 
slight associations between methylation patterns and disease recurrence.
Conclusions: Pyrosequencing is the ideal procedure for the quantitative 
evaluation of epigenetic alterations in normal and malignant prostatic tissue. Our 
data suggest that gene promotor methylation patterns in GSTP1, APC, RASSF1a 
and TNFRSF10C may facilitate the determination of transformed and normal 
prostatic tissues. Methylation status in specific promotor-/exon-1-areas (APC, 
RASSF1a, Endoglin) might be even of prognostic value.
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introduction & objectives: Several members of Ras association domain family 
(RASSF) are frequently silenced in human cancer and supposed to be tumor 
suppressors. The objective of this work was to characterize functional significance 
of epigenetic inactivation of RASSF10, a newly identified member of RASSF, in 
prostate carcinoma (PCa).
Materials & Methods: To evaluate the role of DNA-methylation in silencing of 
RASSF10, three PCa cell lines (DU145, 22RV1, LNCaP), 83 PCa primary tumor 
samples (51 pT1-2, 32 pT3-4) and 52 corresponding non-tumorous samples were 
subjected to RASSF10 bisulfite pyrosequencing. Furthermore, we analyzed the 
effect of 5-aza-2-deoxycytidine (5-aza-dC) and trichostatin A (TSA) on RASSF10 
mRNA expression in PCa cell lines. To investigate the functional role of RASSF10 
in PCa malignancy, we introduced pCMV-Tag1 plasmid containing full-length 
RASSF10 cDNA into LNCaP cells lacking endogenous RASSF10 expression. The 
effect of RASSF10 overexpression was examined by colony formation test and 
apoptosis assay (TUNEL).
results: Among cell lines, LNCaP exhibited the highest RASSF10 methylation 
grade (median=77%) followed by 22RV1 (20.7%) and DU145 cells (6.14%). 
A weak expression of RASSF10 was detected in DU145 cells and a complete 
silencing in 22RV1 and LNCaP. A significant increase of RASSF10 expression was 
induced by TSA in all three PCa cell lines and additional gain of expression with 
the combination of 5-aza-dC/ TSA. Comparing to LNCaP cells baring empty vector, 
the RASSF10 transfected cells formed significantly fewer colonies (101.6±13 vs. 
56±15.5, p=0.0018) and showed more than two fold increase of apoptosis rate. 
Among matched malignant and non-malignant prostate tissue, significantly more 
tumor samples (11) showed increased RASSF10 methylation then non-tumoral 
tissue (3) (21.1% vs. 5.8%, p=0.041). Hypermethylation of RASSF10 correlated 
with higher Gleason score (≥7 vs. <7; 30.4% vs. 10%, p=0.039) and with advanced 
tumor stages (pT3-4 vs. pT1-2; 28.1 % vs. 7.8%, p=0.027). The methylation rate 
of RASSF10 was significantly higher in elderly patients (age of onset 68-78 years, 
n=48) compared to younger patients (age of onset 52-67 years, n=35) (22 9% vs. 
5.7 %, p=0.037).
